CD274 and lung cancer: For some IBP therapies, these support points could be proactively planned according to the treatment schedule; for example, in some healthcare systems, immunotherapies are used for a defined time‐period and then stopped (in the UK, informed by findings from the KEYNOTE024 trial [26], pembrolizumab, for PD‐L1‐positive metastatic non‐small cell lung cancer, is given for a maximum of 24 months and then stopped [27]).